Company ProfilePremium

Caregen Co., Ltd.

Company Profile Analysis

Ticker: 214370.KQ

ESOMAR 23 Corporate BadgeISO Certifications Badge
Caregen Co., Ltd. - Company showcase

Year Founded & Workforce

2001

209 Employees

Caregen Co., Ltd. logo

Caregen Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Caregen Co., Ltd. Overview

Caregen is a Korean, founder-controlled, export-oriented developer and manufacturer of synthetic biomimetic peptides and recombinant growth factors. Its commercial base is a high-margin portfolio of peptide-enhanced dermal fillers, mesotherapy products and cosmeceuticals sold through exclusive or non-exclusive distributors in roughly 130 countries, with exports historically around 95–98% of revenue. Since 2022 it has used the same peptide library to build an oral "metabolic health" franchise — ProGsterol (glucose), MyoKi (muscle) and Korglutide (a GLP-1/IGF-1 dual-acting weight-management peptide) — registered as dietary ingredients via US FDA NDI notifications rather than as drugs. A drug pipeline led by CG-P5, a topical peptide eye drop for wet AMD that completed a US Phase 1 study, provides option value. The investment case has swung sharply in 2025–26: record contract announcements and a KRW 7.7tn peak valuation have been followed by earnings dilution, Middle East receivable write-downs, contract terminations and a 75%+ share-price decline.


Company's own description (Q3 FY2024 quarterly report, paraphrased)

Caregen describes itself as a company that, based on research into biomimetic peptides and growth factor proteins, develops and sells pharmaceuticals, health functional foods, medical devices and cosmetics. Peptides are produced by chemical synthesis at scale; growth factors are produced by genetic engineering. The company states it has built a peptide library protected by more than 730 registered domestic and overseas patents (Sep 2024), and sells "professional therapy" products (fillers, mesotherapy) and functional cosmetics incorporating its peptides, dual-encapsulation and sustained-release technologies in about 130 countries. It describes its planned new businesses as antiviral (COVID-19) medicines, macular-degeneration medicines, and animal medicines and functional feed. The company notes it started in 2001 developing protein chips for cancer diagnosis, pivoted from 2003 to growth factors and biomimetic peptides for devices and cosmeceuticals, and from 2022 entered health functional foods.

Independent characterisation

Business model: Vertically integrated peptide platform — discovery (library of 1,200+ proprietary peptides per the company's BIO USA profile), in-house synthesis (Hwaseong peptide plant, 10 tonnes/year design capacity), finished-goods manufacture (Gunpo plants 1 and 2), and B2B export to country distributors. Distribution partners typically bear local registration costs and timelines (Dealsite, 2023 company interview).

Revenue model: Overwhelmingly product sales (devices, cosmeceuticals, dietary supplements, bulk ingredients). Licensing revenue: none disclosed. The Q3 FY2024 report states the company had no licence-out, licence-in or technology-alliance contracts. Long-term "supply agreements" announced in the press are frequently framework or non-binding agreements whose value depends on partner orders — a structural feature that has repeatedly produced gaps between headline contract values and booked revenue.

Value-chain position: Upstream (API/ingredient) through finished product; no direct-to-consumer retail of note; no domestic Korean sales of the peptide supplements (the company has said Korean regulators do not recognise synthetic peptides as health-food ingredients — Dealsite, Aug 2025).

Customers: Country distributors, aesthetic clinics (indirectly), pharmaceutical and nutraceutical distributors (e.g., IFA Celtics Mexico, Atabay Türkiye, Li Shizhen Pharmaceutical China, 2San USA), and cosmetics brand owners for raw peptides (e.g., BASF supply agreement, 2020).

End-markets: Medical aesthetics (fillers, mesotherapy, hair-loss), cosmeceuticals, dietary supplements (glycaemic control, weight management, sarcopenia), and, prospectively, ophthalmology (wet AMD, dry eye) and drug delivery (Luxidase platform).

Strategy

Stated strategic themes (management statements, paraphrased)

Peptide platform expansion: Grow from aesthetics into supplements, pharmaceuticals and delivery platforms, leveraging a large unpatented reserve of protein/peptide candidates (company statement, Jul 2025: more than 1,200 unpatented candidates).

"Metabolic health portfolio": Korglutide (weight), MyoKi (muscle), ProGsterol (glucose) marketed as a bundle through one partner per country, with partners funding registration.

US mainstream retail entry: via 2San, positioning FDA NDI-notified synthetic peptides as a compliant alternative to grey-market research peptides.

Transition toward a drug developer: CG-P5 licensing/co-development, CG-T1, an oral obesity drug (clinic entry targeted end-2026), and Luxidase licensing.

2026 framed by the CEO as the turning point: where global sales begin in earnest (Venturesquare, May 2026).

Initiatives in the last 24 months

InitiativeDateDetail
Korglutide global out-supply campaignJul 2025 – Feb 2026Mexico, Canada, Thailand, Türkiye, Brazil, China contracts; Lebanon and Mexico registrations; US NDI
Dividend policyFeb 2025Two dividends per year; consolidated payout of at least 30% for three years (Smart Today, Feb 2025)
Value-up plan / treasury-share useMar 2026Articles amended; plan to sell 383,577 treasury shares (base price KRW 130,352, ~KRW 50bn) in H1 2026 to fund CG-P5/CG-T1 trials. Not executed; at KRW 43,750 the block would raise only c. KRW 16.8bn and management said it would not enlarge the sale (Dealsite, Sep 2026)
R&D commitmentOngoingQ3 FY2024 report commits to at least 5% of revenue on R&D; H1 FY2026 ratio 5.14%
Luxidase / Hyalux launchFeb–Apr 2026Delivery-platform commercialisation and licensing outreach (Estée Lauder visited the EURETINA/CPHI Milan booth in Oct 2026 per Finance Scope)
BD partneringJun 2026BIO USA 2026: pre-arranged meetings with 25+ companies incl. Eli Lilly, AbbVie, Bayer, Daiichi Sankyo, Santen
ESG / sustainability commitments——
Cost programmes2,025Management cited peptide production efficiency and R&D cost optimisation (Q3 FY2025 commentary); no quantified target

Medium-term targets and guidance record

No current quantified revenue or margin guidance: was found for FY2026.

Guidance credibility record: FY2023 guidance of KRW 150bn (incl. KRW 70–80bn ProGsterol) cut to KRW 80bn in Dec 2023 (actual KRW 79.2bn); a 2025 target of KRW 100bn+ in supplement revenue (Dealsite, Aug 2025) compares with actual FY2025 supplement revenue of KRW 5.6bn.

Products & Services

Professional therapy (medical devices: fillers, mesotherapy) — exported

Brand / productDescriptionTarget customerNotes
Revofil (incl. Fine, Aquashine, Aquashine BTx, Aquashine Platinum / BR Platinum, Ultra)Peptide-containing hyaluronic-acid fillers and skin boosters; Aquashine BTx positioned as "botulinum-like" peptide fillerAesthetic clinics via distributorsCE marks 2011–2019; Revofil Ultra domestic clinical trial plan approved by MFDS (2023)
Prostrolane; Prostrolane B-Series (Inner B, Natural B, Blanc B, Inner BSE)Face/body/obesity injectable mesotherapy and fillersClinicsCE 2015, 2017, 2018
CG Dimono PTxPeptide-based dermal filler with "immediate effect"; renewed formulation presented at IMCAS Jan 2026ClinicsCE Apr 2023; core of 2024 Middle East three-country supply announcement
CG Styler 600Body-contouring injectableClinicsCE May 2020
Dr.CYJ (Hair Filler)Peptide injectable for hair-loss improvementClinicsCE Mar 2016; UK MHRA registration May 2023
Dermaheal (mesotherapy solutions incl. HL, SB)Face and hair mesotherapyClinicsFirst CE 2009
Intracisc / LineviscJoint fillersClinicsCE Dec 2018

Pricing: not publicly disclosed.

Cosmeceuticals

BrandDescription
DermahealPeptide/growth-factor skincare (anti-wrinkle, regeneration)
PuriluxWhitening
Pim-Pim-PaulAnti-inflammatory/acne
PTxHome-care "botulinum-like" anti-wrinkle line
Dr.CYJ iDR / pDRDamaged-hair repair (CG-Follicare "hair bond repairing" peptide; company-reported clinical repair within 5 minutes lasting 7 days)
Pelo Baum / Pelo Baum PlusHair-loss shampoos, conditioners, revitalising solution (MFDS functional cosmetic registration Jul 2023)
RenokinScalp care (listed by Simply Wall St company description)
NeovertSkincare (listed by Simply Wall St company description)

Health functional foods / dietary supplements

ProductIngredient / mechanism (company-described)Regulatory statusKey commercial events
ProGsterolDeglusterol: synthetic peptide improving insulin-receptor sensitivity; glucose management for type 2 diabetes/pre-diabetesUS FDA NDI (Mar 2022); Philippines FDA (2020/2023); Halal (2023); EU novel food application in final stage (May 2026)Iran launch with physician prescribing (May 2024); Pakistan approval (May 2024); Farmabol Poland USD 5.7m/3 years (May 2026)
MyoKiMyostatin-inhibiting peptide for muscle massUS FDA NDI; India registrationIFA Celtics Mexico USD 33.29m/5 years (Aug 2025). Company-reported 12-week sarcopenia study: limb muscle +2.52%, grip strength +5.2–6.2%
KorglutideSeven-amino-acid oral peptide described as GLP-1R/IGF-1R dual-acting; one daily sachetUS FDA NDI (30 Jan 2026); Lebanon registration (Jul 2025); Mexico COFEPRIS registration as "Trimtide" (Feb 2026); Thai registration filed (2025)India 100-patient, 12-week study: mean weight loss 10.78%, ~72% of loss as fat, muscle loss 0.27 kg (company-reported); second 200-subject study in normal-BMI/high-body-fat adults

Raw materials (B2B ingredients)

About 20 growth factors (e.g., CG-EGF) and around 300 peptides (e.g., CG-Purilux) and mixtures sold under the Caregen name; exclusive supply of four patented peptides to BASF since 2021 (Q3 FY2024 report).

Pipeline / platform technologies (pre-commercial)

AssetIndication / useStage (latest public)
CG-P5Wet AMD; topical VEGFR2-inhibiting peptide eye dropUS Phase 1 completed (NCT06132035); results presented at Retina World Congress 2026, ASRS (Jul 2026) and EURETINA (Oct 2026); Phase 2 planned (incl. Eylea combination and dry AMD)
CG-P5 (dry AMD)Geographic atrophy / dry AMDPreclinical completed
Diabetic retinopathy (CG-P5 mechanism)DRPreclinical completed
CG-T1Dry eye; PAC1R activation, anti-inflammatory eye dropPreclinical
SpikeDownCOVID-19 / pulmonary fibrosis; nasal sprayPhase 1 completed (Israel, Aug 2023)
Oral obesity drug (unnamed)Obesity (drug, not supplement)Animal studies completed; clinical entry targeted end-2026 (CEO, Aug 2025)
Hyperhidrosis peptideHyperhidrosisHuman application study completed
HyaluxTen-amino-acid peptide mimicking hyaluronidaseCosmetic commercialisation targeted 2026 (CEO, Feb 2026)
LuxidaseTopical drug/ingredient delivery platform (company claims 4–5x skin permeation)Unveiled at in-cosmetics Global, Apr 2026; licensing discussions
Animal health peptidesFeline peritonitis, pet allergyResearch

Financial Narrative

Income statement (consolidated)

Sources: OpenDART via Bullstory and Butler (FY2021–FY2025). FY2021 growth derived against FY2020 revenue of KRW 60.3bn (company release, Mar 2021). Revenue CAGR FY2021–FY2025: 5.4% (derived).

Additional FY2025 detail (OpenDART via Simply Wall St and ValueLine): cost of revenue KRW 20.6bn, gross profit KRW 52.2bn (gross margin 71.7%), SG&A KRW 31.8bn (up 51.1% YoY), of which bad-debt expense KRW 12.0bn (FY2024: KRW 0.5bn). Pre-tax income KRW 22.4bn; tax KRW 2.3bn. EBITDA KRW 27.1bn (ValueLine), EBITDA margin 37.2%.

Per-share data

FY2022–FY2023: Q3 FY2024 report (split-adjusted). FY2025: ValueLine. FY2024: derived (net income / c. 48.95m weighted shares) — not company-reported.

Year-end dividend per share

Interim dividends (paid each July) were c. FY2026 interim: KRW 200/share (KRW 9.77bn), declared 3 Jul 2026.

Quarterly run-rate (consolidated, preliminary/fair-disclosure basis)

Q1 FY2025–Q1 FY2026: DART preliminary results (StockHub summary; Smart Today for Q3 FY2025). Q2 FY2026 is derived from ValueLine trailing-twelve-month (TTM) figures at Mar-2026 and Jun-2026 (revenue TTM KRW 74.89bn; operating income TTM KRW 18.24bn; net income TTM KRW 22.87bn); no preliminary Q2 FY2026 release was found. Derived H1 FY2026: revenue c. KRW 41.5bn (+5% YoY), operating income c. KRW 15.4bn, net income c. KRW 16.0bn.

Balance sheet (consolidated)

Sources: Q3 FY2024 report (FY2022–FY2023); ValueLine/OpenDART (FY2024–FY2025). Liquid assets FY2024–FY2025 reconcile to Dealsite (Apr 2026: KRW 44.3bn → KRW 29.1bn). Net debt excludes lease liabilities (not separately verified). FY2025 totals (assets KRW 231.3bn, liabilities KRW 18.8bn, equity KRW 212.5bn) confirmed by Kormedi (Aug 2026).

30 June 2026 (H1 FY2026, ValueLine): total assets KRW 241.3bn; cash KRW 5.9bn; current FVPL assets KRW 29.7bn (liquidity c. KRW 35.6bn); receivables KRW 30.8bn; inventories KRW 23.8bn; PP&E KRW 124.5bn; liabilities KRW 22.6bn; equity KRW 218.7bn; no borrowings.

Cash flow

Source: OpenDART via Bullstory. The negative FY2022 figure is as reported by the aggregator and likely reflects classification of financial-asset movements; not independently reconciled.

FY2023 and FY2024 dividends from Q3 reports (no Q4 payments); FY2025 from ValueLine. FY2024 buyback derived from the change in treasury stock (KRW 67.2bn → KRW 72.2bn; 263,451 shares acquired Sep–Oct 2024).

FY2025 capital expenditure (ValueLine): PP&E KRW 3.9bn plus intangibles KRW 1.1bn; free cash flow c. KRW 13.7bn (derived: OCF minus capex and intangibles). FY2024 capex was dominated by the Daechi-dong building: PP&E additions of KRW 65.8bn in 9M FY2024 alone. TTM to Jun-2026: OCF KRW 26.1bn, capex KRW 4.7bn, FCF c. KRW 21.4bn, dividends paid KRW 21.4bn.

Key ratios (derived, ending-balance basis)

  • Inventory turnover (Dealsite, company-basis): 1.48x FY2024, 1.01x FY2025.

  • Interest coverage and net debt/EBITDA: not meaningful (no borrowings; net cash).

  • ROIC: not computed (invested-capital basis not disclosed; with almost no debt, ROE is the operative return measure).

  • Cash conversion cycle: not computable on a consistent basis; the DSO deterioration is the material signal.

  • ValueLine-reported TTM ROE at Jun-2026: 10.46%.

Commentary on trends, inflections and drivers

  1. Growth stalled after FY2023. Revenue compounded 16–17% in FY2022–FY2023 (ProGsterol launch), slowed to 4% in FY2024 and contracted 11.8% in FY2025. Management attributes FY2025 to the CG-DIMONO PTX renewal, deliberate supply restraint to the Middle East, delayed partner registrations of supplements and deferral of some revenue into 2026 (Dealsite, Apr 2026).

  2. Margin compression is partly non-cash. Operating margin fell from 51.0% (FY2023) to 28.0% (FY2025). Of the KRW 13.9bn decline in operating income in FY2025, the KRW 11.5bn increase in bad-debt expense explains most of it: the company provisioned receivables from Iran and other Middle East customers as the regional war looked likely to persist; credit-impaired receivables overdue more than six months reached c. KRW 17.8bn and cumulative impairment rose from KRW 0.6bn to KRW 12.6bn (Dealsite, Apr 2026). Gross margin remained above 70%.

  3. Working-capital quality has deteriorated. Receivables rose from KRW 7.0bn (FY2022) to KRW 30–33bn (FY2024–FY2025) while revenue grew only 5%, pushing DSO from c. 37 to c. 150 days. Inventories rose 25% in FY2025 (products +21.7%, raw materials +51.9%), which the company describes as pre-stocking for 2026.

  4. The cash buffer has been spent. Liquid financial assets fell from KRW 140.5bn (FY2022) to KRW 29.0bn (FY2025) as the company bought a Seoul building (c. KRW 65bn, debt-free) and paid dividends exceeding earnings (FY2025 payout 106.3%). The balance sheet remains unlevered, but optionality to fund Phase 2 trials internally is materially lower than two years ago.

  5. Early-2026 recovery is uneven. Q1 FY2026 revenue of KRW 22.7bn was a record quarter at a 45% margin; derived Q2 FY2026 operating income of c. KRW 5.2bn suggests additional bad-debt charges (TTM bad-debt expense rose from KRW 12.0bn to KRW 14.7bn by June 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityLocationActivityOwnershipStatus

Caregen Co., Ltd.

Korea

Parent; all operating activity

—

Operating

Caregen Biopharma Inc.

USA (Chicago)

Medical/pharmaceutical R&D

100%

Assets KRW 37m at end-FY2024; zero assets, revenue and net result reported for FY2025 and 2026 YTD (Dealsite, Sep 2026) — effectively dormant

Zhe Jiang Ke Yi Kai Jian Sheng Wu Ke Ji Co., Ltd.

China

Cosmetics wholesale/retail

49% (associate)

Loss-making; FY2025 revenue KRW 4.7bn, net loss KRW 0.2bn, liabilities KRW 9.2bn vs assets KRW 2.1bn (capital impairment) — Dealsite, Apr 2026

Zhe Jiang Dayimei Health Technology Co., Ltd.

China

Cosmetics wholesale/retail

6.67% (associate via board seat)

Carried at nil

CYJ International Company Ltd.

Hong Kong

JV

35%

Liquidated by 30 Sep 2024

CYJ International Taiwan Inc.

Taiwan

Equity investment

Minority

Carried at cost KRW 0.3bn

Revenue by Segment

Product groupFY2022FY2023

Professional therapy total (KRW Bn)

53.6554.44

Professional therapy - face (KRW Bn)

32.6931.28

Professional therapy - hair (KRW Bn)

14.3915.20

Professional therapy - body (KRW Bn)

5.447.40

Professional therapy - joint (KRW Bn)

0.930.56

Cosmeceuticals (KRW Bn)

11.9910.89

Raw materials - peptides and growth factors (KRW Bn)

4.323.09

Health functional foods (KRW Bn)

0.2112.20

Other and accounting adjustments (KRW Bn)

-1.07-1.42

Total revenue (KRW Bn)

69.1079.21

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%)

Product groupFY2022FY2023

Professional therapy (%)

77.668.7

Cosmeceuticals (%)

17.313.8

Raw materials (%)

6.23.9

Health functional foods (%)

0.315.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (FY2022–FY2025)

MetricFY2022FY2023FY2024FY2025

Health functional food revenue (KRW Bn)

0.2112.2012.615.60

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

59.169.179.282.672.8

Operating income (KRW Bn)

28.233.640.434.220.4

Net income (KRW Bn)

25.227.239.932.320.1

Operating margin (%)

47.748.651.041.428.0

Net margin (%)

42.639.450.439.127.6

Revenue growth YoY (%)

-2.016.914.64.3-11.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data

MetricFY2022FY2023FY2024FY2025

Basic EPS (KRW)

556813660374

Diluted EPS (KRW)

556813660374

Per-Share Data (FY2023–FY2025)

MetricFY2023FY2024FY2025

Year-end DPS (KRW)

400400200

Income Statement

MetricQ1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026

Revenue (KRW Bn)

21.318.117.116.322.718.8

Operating income (KRW Bn)

10.27.49.9-7.110.25.2

Net income (KRW Bn)

8.44.810.2-3.311.74.3

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

234.1247.3240.7231.3

Cash and cash equivalents (KRW Bn)

5.231.55.18.9

Short-term financial instruments (KRW Bn)

71.480.90.00.0

Current FVPL financial assets (KRW Bn)

63.920.339.220.2

Total liquid financial assets (KRW Bn)

140.5132.744.329.0

Trade receivables, net (KRW Bn)

7.013.133.030.0

Inventories (KRW Bn)

10.318.718.122.6

Property, plant and equipment (KRW Bn)

60.464.0125.6125.4

Intangible assets (KRW Bn)

3.94.75.05.1

Goodwill (KRW Bn)

0000

Short-term borrowings (KRW Bn)

0000

Long-term borrowings (KRW Bn)

0000

Net debt (KRW Bn)

-140.5-132.7-44.3-29.0

Total liabilities (KRW Bn)

18.120.017.718.8

Total equity (KRW Bn)

216.0227.3223.0212.5

Current assets (KRW Bn)

158.9166.496.483.1

Current liabilities (KRW Bn)

10.511.38.18.4

Working capital (KRW Bn)

148.4155.188.374.8

Treasury stock at cost (KRW Bn)

67.367.272.272.2

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

51.9-27.728.613.518.6

Dividends & Capital Returns

MetricFY2023FY2024FY2025

Cash dividends paid (KRW Bn)

28.531.431.1

Share buybacks (KRW Bn)

0.05.00.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

12.617.614.59.5

ROA (%)

11.616.113.48.7

Current ratio (x)

15.214.712.09.9

Total liabilities to equity (%)

8.48.87.98.8

Debt to equity (%)

0000

Asset turnover (x)

0.300.320.340.31

Days sales outstanding (days)

3761146150

Revenue by Region

RegionFY2024FY2025

Asia incl. Middle East (KRW Bn)

49.232.4

Rest of world (KRW Bn)

33.440.4

Total (KRW Bn)

82.672.8

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

27,42027,50028,80071,800

Year-end market cap (KRW Bn)

1,4731,4771,5473,857

Valuation Multiples

MultipleCaregenBasis / source

P/E (TTM)

87.4x

ValueLine

P/B

9.14x

ValueLine

EV/Sales (TTM)

c. 26x

Derived: EV ≈ KRW 1,962bn (market cap less c. KRW 35.6bn liquid assets at Jun 2026) / TTM revenue KRW 74.9bn

EV/EBITDA (TTM)

c. 62x

Derived: EV / TTM EBITDA KRW 31.4bn (ValueLine)

Dividend yield

1.08%

Butler

Peer reference

Classys P/E 15.0x (Butler, Oct 2026); Hugel FY2026E P/E 18.9x and Pharma Research 15.9x (Alphadistill, 2026)

Mixed dates/bases

Analyst Conclusions

Guidance and expectations

  • Management qualitative guidance: global sales to accelerate from Q2 FY2026, led by North and Latin America; 2026 described as a turning point (May 2026). No numeric FY2026 guidance.

  • Consensus growth expectations: not publicly disclosed (no consensus); Investing.com notes analysts expect revenue growth this year (unquantified).

  • Run-rate check: derived H1 FY2026 revenue c. KRW 41.5bn (+5% YoY) and OP c. KRW 15.4bn (margin c. 37%) imply a FY2026 revenue trajectory of roughly KRW 80–85bn absent a step-change in H2 — a dossier extrapolation, not guidance.

Bull case (grounded in the data above)

  1. Supplements go mainstream in the US and China. NDI status plus 2San's pharmacy access and Li Shizhen's e-commerce launch could convert a small share of KRW 1.1tn+ of headline contract value into revenue at 70%+ gross margins, using already-installed capacity (peptide utilisation below 25%).

  2. CG-P5 licensing. Phase 1 data superior to aflibercept on IRF clearance in a 45-patient study, plus 25+ big-pharma meetings, could yield an upfront/milestone deal that re-rates the company as a drug developer.

  3. Earnings normalisation. FY2025 was depressed by a KRW 12.0bn non-cash provision; Q1 FY2026 already produced a 45% margin. Any recovery of Middle East receivables would reverse charges.

Bear case

  1. Contract-conversion failure is structural, not cyclical. RONESCA (1.2% in nine years), the 2016 terminations and the FY2023/FY2025 guidance misses suggest headline values systematically overstate economic substance.

  2. Valuation remains demanding after the crash. At c. 87x TTM earnings and c. 26x EV/Sales, the shares price in success that FY2025–H1 FY2026 numbers do not yet show; Korean aesthetic peers with faster growth trade at 15–19x P/E.

  3. Funding and governance constraints. Liquid assets of c. KRW 29–36bn, dividends exceeding earnings, a failed treasury-sale plan, falling R&D and repeat disclosure sanctions limit the capacity to fund Phase 2 internally and sustain a governance discount.

Catalysts and monitorables (next 12 months)

ItemTimingWhat to watch
Q3 FY2026 results6 Nov 2026Supplement revenue, bad-debt charges, receivable collection
FY2026 results and dividendFeb–Mar 2027Whether payout again exceeds earnings
CG-P5 partnering / Phase 2 startOngoingAny licence, upfront size, Phase 2 IND
Oral obesity drug clinical entryEnd-2026 targetIND/CTA filing
Li Shizhen sell-throughQuarterlyOrder flow vs c. KRW 111bn/yr implied run-rate
US 2San retail listingsH2 2026Confirmed shelf placements at named chains
EU novel-food decision (Deglusterol)2026–27Authorisation
RONESCA contract expiryJul 2027Renewal, termination or write-off
Treasury-share cancellation deadlinec. 2027Cancellation vs disposal
KRX penalty pointsOngoingAny further designations
Middle East normalisationOngoingResumption of Iran/Gulf shipments

Analyst verdict

Caregen is a genuinely differentiated peptide manufacturer with an unusually profitable core, but it is not — on the evidence of the past three years — a reliable compounder. The company's audited numbers tell a sober story: revenue has grown at only 5.4% a year since FY2021, operating income has halved from its FY2023 peak, receivables have quadrupled, and the cash cushion that once covered two years of revenue has shrunk to under five months of sales after a property purchase and dividends paid out of retained earnings. Against that, the headline narrative — more than KRW 1.1tn of supply agreements, US NDI status, a 45-patient CG-P5 study that outperformed Eylea on fluid clearance — remains largely unconverted into revenue or licensing cash.

The 76% share-price collapse since February 2026 has removed much of the speculative premium, yet the stock still trades at roughly 87x trailing earnings and about 9x book, multiples that require either a step-change in supplement sell-through or a validated CG-P5 partnership. Both are plausible; neither is evidenced. The governance overlay — founder control near 65%, recurring disclosure sanctions, an audit disclaimer in recent memory and an R&D budget moving opposite to the drug-developer pitch — warrants a persistent discount.

Our synthesis: Caregen is an option-rich but execution-poor asset. The two variables that matter most are measurable within twelve months — quarterly supplement revenue (did Q2 FY2026's 29% share hold and grow?) and a signed, value-disclosed CG-P5 licence. Until either appears, earnings quality (bad-debt trends, DSO, payout above 100%) is the more reliable guide than contract announcements.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation

Chung Yong-ji (정용지)

Founder, CEO, Representative Director; also leads research

Since Aug 2001

Born 25 Feb 1970; BS Genetic Engineering, Sungkyunkwan University; MS Biology, University of Texas at San Antonio; PhD Animal Science, Cornell (Wikipedia: 1996; company filing: 2000 — discrepancy); postdoctoral research, Northwestern University Feinberg School of Medicine (2000–2001)

FY2025 salary KRW 1.675bn (Dealsite, Apr 2026); estimated c. KRW 14bn in FY2025 dividends; FY2019 pay KRW 1.0bn

Kim Eun-mi (김은미)

Vice President, inside director; R&D management (vice-head of central research institute)

Joined 2003; director 2014–2019; VP since 2020; re-elected inside director Mar 2024

MSc Immunology, Hanyang University (2007)

Not publicly disclosed for FY2025

Ra Hee-sook (라희숙)

Vice President (signatory officer for periodic reports)

———

Jeong Tae-jin (정태진)

CFO (as quoted in Oct 2018)

———

“—” = not publicly disclosed.

Major Shareholders

HolderShares% of issuedDate / source

Chung Yong-ji

34,011,29163.31

29 Jul 2026 filing (Kormedi)

Chung Yeon-woo (elder son)

386,6350.72

29 Jul 2026

Kim Eun-mi

201,5500.38

29 Jul 2026

Chung Min-woo (younger son)

25,6350.05

29 Jul 2026

Kim Joong-hyun (outside director)

3,1790.01

29 Jul 2026

Controlling group total

34,629,568

64.47

29 Jul 2026

Treasury shares

4,844,2169.02

H1 FY2026

Amorepacific Group

369,794 (at acquisition)

c. 0.7

—

Free float (approx.)

c. 14.2m

c. 26.5

Derived

Competitive Landscape

Competitors by Segment

Business lineDirect competitors (named)Notes

Dermal fillers / skin boosters

Galderma (Restylane, Sculptra), AbbVie / Allergan Aesthetics (Juvéderm), Merz (Radiesse), LG Chem (YVOIRE), Hugel (The Chaeum / Revolax), Pharma Research (Rejuran), Medytox, Jetema

Caregen differentiates on peptide-added fillers; scale disadvantage

Hair-loss injectables / cosmeceuticals

Pharma Research (cosmetics), Amorepacific, numerous K-beauty brands

Fragmented

Cosmetic peptide ingredients

Lubrizol (Lipotec), Croda (Sederma), DSM-Firmenich

Caregen also supplies BASF

Weight management

Novo Nordisk (Wegovy, oral semaglutide), Eli Lilly (Zepbound, orforglipron pipeline); grey-market "research peptides"

Korglutide sold as a supplement, not a drug; efficacy claims are company-reported

Glucose management supplements

Generic nutraceuticals (berberine, chromium etc.)

ProGsterol premium pricing cited by Nomura (2024) as a barrier

Wet AMD

Regeneron/Bayer (Eylea, Eylea HD), Roche (Vabysmo, Lucentis), Novartis (Beovu), aflibercept biosimilars

CG-P5 targets the non-invasive niche

Aesthetic devices (adjacent KOSDAQ peer)

Classys (HIFU/RF)

Valuation benchmark rather than direct competitor

Peer Comparison FY2025

CompanyRevenueOperating incomeOperating margin (%)Revenue growth (%)R&D / revenue (%)

Caregen

72.820.428.0-11.87.9

Pharma Research

535.7214.240.0——

Hugel

425.1201.647.414.0—

Classys

336.8170.650.738.6—

Company Snapshot

$51.2M

Revenue

209

Employees

2001

Founded

Anyang, South Korea

Headquarters

SWOT Analysis

Strengths

  • Gross margin of 71.7% in FY2025 and operating margins of 47.7–51.0% in FY2021–FY2023 (OpenDART) — among the highest of any KOSDAQ healthcare company.
  • Zero borrowings in every year FY2022–FY2025; total liabilities only KRW 18.8bn against equity of KRW 212.5bn (FY2025).
  • Large IP estate: 740 registered patents and 1,218 applications at Sep 2024 (Q3 FY2024 report); 238 new applications in FY2025.
  • Three US FDA NDI-notified peptide dietary ingredients (Deglusterol Mar 2022; MyoKi; Korglutide Jan 2026).
  • Vertically integrated synthesis: Hwaseong plant rated at 10 t/yr, peptide utilisation only 16.8% in 9M FY2024 — capacity to scale without capex.
  • CG-P5 Phase 1 data (83% IRF clearance vs 60% for aflibercept at day 56) accepted for oral presentation at ASRS 2026 and presented at Retina World Congress and EURETINA.

Weaknesses

  • Sub-scale: FY2025 revenue KRW 72.8bn vs Hugel KRW 425.1bn and Pharma Research KRW 535.7bn.
  • Poor conversion of announced contracts: RONESCA 1.2% fulfilled after nine years; two 2016 contracts terminated in May 2026.
  • Receivable quality: DSO c. 150 days (FY2025) vs c. 37 days (FY2022); KRW 12.6bn cumulative impairment.
  • Guidance misses: FY2023 guidance cut 47%; FY2025 supplement revenue KRW 5.6bn vs KRW 100bn+ aspiration.
  • Declining R&D intensity (5.14% in H1 FY2026) and a dormant US R&D subsidiary despite drug-developer positioning.
  • Disclosure record: FY2018 audit disclaimer and multiple unfaithful-disclosure designations (2024, Jun 2026).

Opportunities

  • US mainstream retail via 2San (CVS, Walgreens, Walmart, Target targeted) for NDI-notified peptides.
  • China via Li Shizhen (c. KRW 557bn headline, five years) — e-commerce launch from Feb 2026.
  • Latin America: Trimtide (Mexico) launched Mar 2026; BCMED (Brazil) from Jan 2026.
  • CG-P5 out-licensing after Phase 1; 25+ big-pharma meetings at BIO USA 2026.
  • Luxidase/Hyalux platform licensing to cosmetics majors (Estée Lauder discussions reported Oct 2026).
  • EU novel-food authorisation for Deglusterol (final stage per May 2026), opening EU-wide ProGsterol sales.

Threats

  • Middle East war since Mar 2026: historically important Iranian and Gulf customers; bad-debt charges continued into 2026 (TTM KRW 14.7bn at Jun 2026).
  • Prescription oral GLP-1 drugs from Novo Nordisk and Eli Lilly could compress demand or the price point for a supplement positioned against injectables.
  • US regulatory action against peptide supplements (Hanyang notes regulatory direction could halt grey-market sales at any time — a precedent risk for the category).
  • Contract-termination contagion: RONESCA expires Jul 2027; further write-offs/terminations possible.
  • Korean Commercial Act amendment (Mar 2026) mandates cancellation of legacy treasury shares within 18 months, limiting their use as a funding source.
  • Share-price collapse (KRW 153,800 → KRW 36,650) reduces equity-funding capacity for Phase 2 trials.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7–9 May 2025Bio Korea 2025: Korglutide interim data (−9.46% weight at 12 weeks)First public efficacy claim for the GLP-1 supplement
12 May 2025Hanyang Securities "Not Rated" report flags imminent CG-P5 licensing; stock +25.7% intraday to KRW 29,550Start of 2025–26 re-rating
13 May 2025Q1 FY2025: revenue KRW 21.3bn, OP KRW 10.2bnMargin near 48%
Jul 2025Lebanon registers Korglutide as a health foodFirst registration of an oral GLP-1-analogue peptide supplement (company claim)
11–14 Jul 2025IFA Celtics (Mexico) Korglutide supply, USD 42mFirst large Korglutide deal; stock +17%
29 Jul 2025Korglutide India trial IR: −10.78% weight, minimal muscle lossUnderpins licensing pitch
12 Aug 2025Q2 FY2025: revenue KRW 18.1bn (−11.5% YoY), OP KRW 7.4bnTop-line weakness emerges
12 Aug 2025VANA Health (Canada) USD 158m, three supplementsLargest North American agreement
13 Aug 2025IFA Celtics MyoKi, USD 33.29mSecond Mexico deal
20–21 Aug 2025Unify Chemical (Thailand), KRW 50bnSoutheast Asia entry
26 Aug 2025CEO at CPHI Korea: oral obesity drug candidate, clinic entry targeted end-2026Pipeline expansion
12 Sep 2025Atabay (Türkiye), USD 7.6mPharmacy coverage c. 90% of Türkiye
14 Nov 2025Q3 FY2025: revenue KRW 17.1bn (−15.9%), OP KRW 9.9bn (−22.2%)Company cites FX-driven order delays, product renewals
Nov 2025MEDICA 2025 (Düsseldorf)Device/filler marketing
2 Dec 2025BCMED (Brazil), USD 56.2m, 5 yearsLatin American expansion
23 Dec 2025Li Shizhen Pharmaceutical (China), c. KRW 557bn, 5 yearsLargest headline contract in company history
21 Jan 2026Li Shizhen chairman visits; first shipments in ChinaExecution step
29–31 Jan 2026IMCAS 2026 (Paris), Emerald sponsor; renewed CG Dimono PTx presentedAesthetics relaunch
30 Jan 2026Korglutide US FDA NDI completedEnables lawful US sale as a dietary ingredient
10 Feb 2026WHX Dubai: Hyalux peptide hyaluronidase to be commercialised in 2026New platform
Feb 2026Share price peaks at KRW 153,800; market cap above KRW 7.7tn (KOSDAQ top 10)Valuation peak
19 Feb 2026Mexico COFEPRIS registers Korglutide ("Trimtide"); launch from MarchFirst major regulated-market launch
Early Mar 2026US/Israel–Iran war; Korean equities crash on 9 Mar 2026Direct hit to Middle East business; risk-off
Mar 2026FY2025 results: revenue KRW 72.8bn (−11.8%), OP KRW 20.4bn (−40.4%); bad-debt charge KRW 12.0bnEarnings reset
Mar 2026AGM; treasury-share disposal plan (383,577 shares) for R&DFunding plan
Mar–Apr 2026FY2025 final dividend KRW 200/share; FY2025 payout 106.3%Dividends above earnings
Apr 2026in-cosmetics Global (Paris): Luxidase launchedLicensing optionality
24 Apr 2026Hanyang Securities: Caregen as the only NDI-registered synthetic peptide supplier amid a US peptide boomBull thesis restated
30 Apr 2026Q1 FY2026: revenue KRW 22.7bn (record), OP KRW 10.2bn, NI KRW 11.7bnRecovery quarter
12 May 2026Farmabol (Poland) ProGsterol, USD 5.7mEU entry; EU novel-food process in final stage
May 2026Vitafoods Europe 2026EU/US marketing
29 May 2026Disclosures of termination (KRW 37.9bn) and >50% amendment (KRW 2.0bn) of 2016 supply contractsCredibility hit
c. May–Jun 20262San (USA) supply agreement; June production on pre-ordersUS retail entry
Jun 2026CPHI China 2026Supplement promotion
22–25 Jun 2026BIO USA 2026 (San Diego): 25+ partnering meetings incl. Lilly, AbbVie, BayerBD activity, no deal disclosed
29 Jun 2026Designated an "unfaithful disclosure corporation" (3.0 penalty points)Repeat governance sanction
3 Jul 2026Interim dividend KRW 200/share (KRW 9.77bn)Dividend maintained
8 Jul 2026Sell-off
Jul 2026CPHI South East Asia: Korglutide and LuxidaseRegional push
17–20 Jul 2026CG-P5 Phase 1 oral presentation at ASRS 2026 (IRF-free rate 83.3%)Scientific validation step
29 Jul 2026CEO buys 3,000 shares at c. KRW 49,397; stock −9.95% that dayToken insider buying
14 Aug 2026H1 FY2026 report filedDerived Q2 OP c. KRW 5.2bn
3 Sep 2026New 52-week low (KRW 45,000 intraday)Down >70% from peak
7–9 Sep 2026Dealsite investigative series: treasury-sale shortfall, R&D decline, RONESCA 1.2% fulfilmentNegative sentiment
Oct 2026EURETINA 2026 (Vienna) and CPHI Milan: CG-P5, CG-T1 data; Estée Lauder discussion on LuxidaseOngoing BD
13–15 Oct 2026Shares fall to KRW 36,650 (15 Oct close); market cap c. KRW 2.0tnCurrent trough

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment: Total revenue to Professional therapy - body: Total revenue rose from KRW 69,100 Mn in FY2022 to KRW 79,210 Mn in FY2023.
Caregen Co., Ltd. — Revenue by Segment: Total revenue to Professional therapy - body
Series (KRW Mn)FY2022FY2023
Total revenue69,10079,210
Professional therapy total53,65054,440
Professional therapy - face32,69031,280
Professional therapy - hair14,39015,200
Professional therapy - body5,4407,400

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.